Telemonitoring in NIV MND (OptNIVent) (OptNIVent)
Primary Purpose
Motor Neuron Disease, Amyotrophic Lateral Sclerosis
Status
Not yet recruiting
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
Telemonitoring via Careportal®
Sponsored by
About this trial
This is an interventional supportive care trial for Motor Neuron Disease, Amyotrophic Lateral Sclerosis focused on measuring non-invasive ventilation, Telehealth, Telemonitoring
Eligibility Criteria
Inclusion Criteria (Patients):
- Confirmed diagnosis of MND with respiratory muscle weakness
- Adults who are capable of informed consent
- Patients for whom we anticipate survival of 6 months or more
- Able to communicate with an interviewer. Alternative communication methods will be used as required in order to mitigate communication difficulties.
Exclusion Criteria (Patients):
- Patients who have declined NIV
Sites / Locations
Arms of the Study
Arm 1
Arm Type
Other
Arm Label
Telemonitoring via Careportal®
Arm Description
Participants will be prompted by the device to answer two sets of questions every week: 10 items (1 nested) in the morning and 16 items (4 nested) in the evening. Also on a weekly basis, patients will be prompted to perform overnight oximetry test, and upload patient-ventilator interaction data (PVI) via Careportal®.
Outcomes
Primary Outcome Measures
Acceptability - Qualitative data through semi-structured interviews and focus groups
Qualitative data will be collected through focus groups with participants, their lay caregivers, and clinicians. Separate focus groups will be conducted for the three participant groups with an option of individual interviews for patients and lay caregivers.
Usability - Qualitative data through semi-structured interviews and focus groups
Qualitative data will be collected through focus groups with participants, their lay caregivers, and clinicians. Separate focus groups will be conducted for the three participant groups with an option of individual interviews for patients and lay caregivers.
Secondary Outcome Measures
Patient Reported Outcome Measurement - Neurological Fatigue Index for MND
13-item questionnaire assessing fatigue experienced by people with motor neurone disease. The questionnaire consists of two sub-scales: Weakness sub-scale and Energy sub-scale. Eight items make up the Summary Fatigue scale with the total scores range from 0 to 24. Higher scores indicate higher levels of fatigue
Patient Reported Outcome Measurement - Epworth Sleepiness Scale
8-item questionnaire to measure general levels of sleepiness. Total scores range from 0 to 24. Higher scores indicate higher levels of sleepiness.
Patient Reported Outcome Measurement - Dyspnoea-12
12-item questionnaire to measure overall breathlessness severity. Total scores range from 0 to 36. Higher scores indicate higher breathless severity.
Patient Reported Outcome Measurement - revised Amyotrophic Lateral Sclerosis Functional Rating Scale
12-item questionnaire to monitor the disease progression covering bulbar, motor and respiratory function. Total scores range from 0 to 48. Higher scores indicate better function.
Patient Reported Outcome Measurement - Hospital Anxiety and Depression Scale
14-item questionnaire to measure anxiety and depression levels. The questionnaire consists of anxiety sub-scale and depression sub-scale. Scores for each sub-scale range from 0 to 21. Higher scores indicate greater anxiety/depression levels.
Patient Reported Outcome Measurement - the World Health Organization Quality of Life Scale-BREF
26-item questionnaire consists of Physical Health domain, Psychological domain, Social relationships domain, and Environment domain in addition to Overall QoL (1-item) and General Health (1-item) facets. Total scores range from 0 to 100. Higher scores indicate indicate higher quality of life.
Patient Reported Outcome Measurement - 5-level EQ-5D
The questionnaire consists of 5-item to measure health based on five domains: Mobility, Self-care, Usual Activities, Pain/Discomfort, and Anxiety/Depression. Each domain has 5 levels indicating worsening health, from having no problems to having severe problems. The questionnaire also contain one visual analogue scale measuring health-reported health: 0 indicates worst health while 100 indicates the best health.
Patient Reported Outcome Measurement - General Satisfaction
6-item General Satisfaction sub-scale from Patient Satisfaction Questionnaire. Total scores range from 6 to 30. Higher scores indicate greater satisfaction.
Patient Reported Outcome Measurement - Access, Availability and Convenience
12-item Access, Availability and Convenience sub-scale from Patient Satisfaction Questionnaire. Total scores range from 12 to 60. Higher scores indicate greater access, availability and convenience.
Self-Reported Outcome Measurement - Caregiving Distress Scale
17-item questionnaire to measure caregiver distress, covering five dimensions: Relationship distress, Emotional burden, Social impact, Care-receiver demands, and Personal cost. Total scores range from 0 to 68. Higher scores indicate greater distress.
Service evaluation
Patient Level Information and Costing System (PLICS)
Full Information
NCT ID
NCT05299372
First Posted
September 21, 2021
Last Updated
March 18, 2022
Sponsor
Liverpool University Hospitals NHS Foundation Trust
1. Study Identification
Unique Protocol Identification Number
NCT05299372
Brief Title
Telemonitoring in NIV MND (OptNIVent)
Acronym
OptNIVent
Official Title
Optimising the Management of Ventilated Patients and Quality of Life in Motor Neurone Disease: a Pilot Study
Study Type
Interventional
2. Study Status
Record Verification Date
March 2022
Overall Recruitment Status
Not yet recruiting
Study Start Date
April 25, 2022 (Anticipated)
Primary Completion Date
October 31, 2022 (Anticipated)
Study Completion Date
December 31, 2022 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Liverpool University Hospitals NHS Foundation Trust
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
5. Study Description
Brief Summary
This is a feasibility study of telemonitoring system for people with MND/ALS, who are on NIV, via a call centre operated by a local clinical commissioning group.
Detailed Description
This study will test the feasibility of previously developed Telehealth system, using a device called Careportal®, to monitor people with MND/ALS who are using non-invasive ventilation (NIV). The Careportal® is a CE marked portable tablet computer device allowing telecommunication between patients and their care team through bespoke question sets, overnight oximetry test, and patient-ventilator interaction(PVI) data. Previously, the weekly telemonitoring via Careportal® was found to be an effective method to monitor symptom changes, allowing clinicians to optimise the care of ventilated patients with MND. This study will assess the practicality of using Careportal® in the care of ventilated patients with MND by monitoring patients through a patient support call centre. The call centre will screen the data and liaise with appropriate clinicians regarding changes of symptoms.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Motor Neuron Disease, Amyotrophic Lateral Sclerosis
Keywords
non-invasive ventilation, Telehealth, Telemonitoring
7. Study Design
Primary Purpose
Supportive Care
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
15 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Telemonitoring via Careportal®
Arm Type
Other
Arm Description
Participants will be prompted by the device to answer two sets of questions every week: 10 items (1 nested) in the morning and 16 items (4 nested) in the evening. Also on a weekly basis, patients will be prompted to perform overnight oximetry test, and upload patient-ventilator interaction data (PVI) via Careportal®.
Intervention Type
Other
Intervention Name(s)
Telemonitoring via Careportal®
Intervention Description
The question sets and overnight oximetry results will be monitored and screened by a call centre commissioned by the Liverpool Clinical Commissioning Group (LCCG). The call centre will screen the weekly data and contact clinicians where appropriate (i.e. NIV team, MND specialist nurse, or patient's GP). PVI data will be examined by NIV physiotherapists, where required, following the contact from LCCG to ensure the maximum benefits of NIV to patients.
Primary Outcome Measure Information:
Title
Acceptability - Qualitative data through semi-structured interviews and focus groups
Description
Qualitative data will be collected through focus groups with participants, their lay caregivers, and clinicians. Separate focus groups will be conducted for the three participant groups with an option of individual interviews for patients and lay caregivers.
Time Frame
Qualitative data will be conducted at 3-month
Title
Usability - Qualitative data through semi-structured interviews and focus groups
Description
Qualitative data will be collected through focus groups with participants, their lay caregivers, and clinicians. Separate focus groups will be conducted for the three participant groups with an option of individual interviews for patients and lay caregivers.
Time Frame
Qualitative data will be conducted at 3-month
Secondary Outcome Measure Information:
Title
Patient Reported Outcome Measurement - Neurological Fatigue Index for MND
Description
13-item questionnaire assessing fatigue experienced by people with motor neurone disease. The questionnaire consists of two sub-scales: Weakness sub-scale and Energy sub-scale. Eight items make up the Summary Fatigue scale with the total scores range from 0 to 24. Higher scores indicate higher levels of fatigue
Time Frame
Baseline and then 6-weekly up to 24 weeks
Title
Patient Reported Outcome Measurement - Epworth Sleepiness Scale
Description
8-item questionnaire to measure general levels of sleepiness. Total scores range from 0 to 24. Higher scores indicate higher levels of sleepiness.
Time Frame
Baseline and then 6-weekly up to 24 weeks
Title
Patient Reported Outcome Measurement - Dyspnoea-12
Description
12-item questionnaire to measure overall breathlessness severity. Total scores range from 0 to 36. Higher scores indicate higher breathless severity.
Time Frame
Baseline and then 6-weekly up to 24 weeks
Title
Patient Reported Outcome Measurement - revised Amyotrophic Lateral Sclerosis Functional Rating Scale
Description
12-item questionnaire to monitor the disease progression covering bulbar, motor and respiratory function. Total scores range from 0 to 48. Higher scores indicate better function.
Time Frame
Baseline and at 3-month and 6-month
Title
Patient Reported Outcome Measurement - Hospital Anxiety and Depression Scale
Description
14-item questionnaire to measure anxiety and depression levels. The questionnaire consists of anxiety sub-scale and depression sub-scale. Scores for each sub-scale range from 0 to 21. Higher scores indicate greater anxiety/depression levels.
Time Frame
Baseline and at 3-month and 6-month
Title
Patient Reported Outcome Measurement - the World Health Organization Quality of Life Scale-BREF
Description
26-item questionnaire consists of Physical Health domain, Psychological domain, Social relationships domain, and Environment domain in addition to Overall QoL (1-item) and General Health (1-item) facets. Total scores range from 0 to 100. Higher scores indicate indicate higher quality of life.
Time Frame
Baseline and at 3-month and 6-month
Title
Patient Reported Outcome Measurement - 5-level EQ-5D
Description
The questionnaire consists of 5-item to measure health based on five domains: Mobility, Self-care, Usual Activities, Pain/Discomfort, and Anxiety/Depression. Each domain has 5 levels indicating worsening health, from having no problems to having severe problems. The questionnaire also contain one visual analogue scale measuring health-reported health: 0 indicates worst health while 100 indicates the best health.
Time Frame
Baseline and at 3-month and 6-month
Title
Patient Reported Outcome Measurement - General Satisfaction
Description
6-item General Satisfaction sub-scale from Patient Satisfaction Questionnaire. Total scores range from 6 to 30. Higher scores indicate greater satisfaction.
Time Frame
Baseline and at 3-month and 6-month
Title
Patient Reported Outcome Measurement - Access, Availability and Convenience
Description
12-item Access, Availability and Convenience sub-scale from Patient Satisfaction Questionnaire. Total scores range from 12 to 60. Higher scores indicate greater access, availability and convenience.
Time Frame
Baseline and at 3-month and 6-month
Title
Self-Reported Outcome Measurement - Caregiving Distress Scale
Description
17-item questionnaire to measure caregiver distress, covering five dimensions: Relationship distress, Emotional burden, Social impact, Care-receiver demands, and Personal cost. Total scores range from 0 to 68. Higher scores indicate greater distress.
Time Frame
Baseline and at 3-month and 6-month
Title
Service evaluation
Description
Patient Level Information and Costing System (PLICS)
Time Frame
At the end of study i.e. at 6-month
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria (Patients):
Confirmed diagnosis of MND with respiratory muscle weakness
Adults who are capable of informed consent
Patients for whom we anticipate survival of 6 months or more
Able to communicate with an interviewer. Alternative communication methods will be used as required in order to mitigate communication difficulties.
Exclusion Criteria (Patients):
Patients who have declined NIV
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Hikari Ando, PhD
Phone
0151529
Email
hikari.ando@nhs.net
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Robert M Angus, MRCP, FRCP
Organizational Affiliation
Liverpool University Hospitals NHS Foundation Trust
Official's Role
Principal Investigator
12. IPD Sharing Statement
Citations:
PubMed Identifier
30912468
Citation
Ando H, Ashcroft-Kelso H, Halhead R, Young CA, Chakrabarti B, Levene P, Cousins R, Angus RM. Incorporating self-reported questions for telemonitoring to optimize care of patients with MND on noninvasive ventilation (MND OptNIVent). Amyotroph Lateral Scler Frontotemporal Degener. 2019 Aug;20(5-6):336-347. doi: 10.1080/21678421.2019.1587630. Epub 2019 Mar 26.
Results Reference
background
Learn more about this trial
Telemonitoring in NIV MND (OptNIVent)
We'll reach out to this number within 24 hrs